About Quanterix
Quanterix is a publicly listed company based in Cambridge (United States) founded in 2007. Assay kits for ultra-sensitive biomarker detection are developed. Quanterix has raised $99.5 million across 15 funding rounds from investors including General Electric, T. Rowe Price and Hercules Capital. The company has 471 employees. Quanterix has completed 2 acquisitions, including Akoya Biosciences and UmanDiagnostics. Its website quanterix.com draws about 46 thousand monthly visits. Quanterix offers products and services including Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development. Its focus areas include Life Sciences, Genomics, Diversified and Life Sciences Platforms and Tools. Its competitors include Bio Rad, Arrakis Therapeutics and NanoString; 2 of its 3 listed competitors have raised funding.
Company details
Quanterix was founded in 2007 in Cambridge, United States, and operates in the biotechnology sector. Assay kits utilizing the Simoa technology are provided for ultra-sensitive biomarker detection. This solution supports research applications across oncology, neurology, cardiology, inflammation, and infectious diseases. Operations focus on enabling disease detection, prognosis, and treatment methods through precise biomarker analysis.
- Headquarters Cambridge, United States
- Employees 471
- Stage Public
- SectorsHealthcare
- Website quanterix.com
- Social LinkedIn X Facebook YouTube
- Legal Name Quanterix Corporation
- Annual Revenue$138.9 M (USD)1.07as on Dec 31, 2025
- Net Profit-$107.15 M (USD)-178.09as on Dec 31, 2025
- EBITDA-$68.49 M (USD)-54.74as on Dec 31, 2025
- Total Equity Funding$99.5M (USD)
in 15 rounds
- InvestorsGeneral Electric
& 13 more
- Employee Count471
- Investments & AcquisitionsAkoya Biosciences
& 1 more
Products & Services of Quanterix
Quanterix offers a comprehensive portfolio of products and services, including Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development.
Kits for ultrasensitive protein biomarker measurement in research.
Automated platform for precise immunoassay detection.
Tailored solutions for specialized biomarker research needs.
Apps and channels of Quanterix
its YouTube channel Quanterix has 490 subscribers and 30 videos.
Videos from Quanterix
The most watched videos on Quanterix's YouTube channel, Quanterix (490 subscribers). Click a video to play it here.
More on Quanterix.
Funding Insights of Quanterix
Quanterix has successfully raised a total of $99.5M across 15 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $99.5M
- Total Rounds 15
- First Round $185,461
(Jul 2008)
- Investors Count 14
Latest 10 of 15 funding rounds of Quanterix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | Grant | – | – | ||
| Jun 2017 | $8.5M | Series D | – | T. Rowe Price | – |
| Mar 2016 | $46M | Series D | – | – | |
| Jul 2015 | $500,000 | Grant | – | – | |
| Jan 2014 | $300,000 | Grant | – | – | |
| Dec 2013 | $999,999 | Series C | – | – | – |
| Nov 2012 | $18.5M | Series C | – | – | |
| Mar 2012 | $2M | Series B | – | – | – |
| Aug 2011 | $6M | Series B | – | – | – |
| Sep 2010 | $2.5M | Series A | – | – | – |
14 investors in total: 14 institutional.
Investors in Quanterix
Quanterix has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include General Electric, T. Rowe Price and Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital fund focused on investing in multiple sectors | baincapitalventures.com | Boston, United States | ||
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital firm | iqt.org | Washington, Dc, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Drugs for Alzheimer's prevention, treatment, and cure are discovered. | 1998 | alzdiscovery.org | New York, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Multiple courses and degrees across diversified streams are offered. | 1852 | tufts.edu | Medford, United States | |
Diversified investment management is offered to clients. | 2015 | trinitascmllc.com | Dallas, United States | |
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States |
Investor details for Quanterix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quanterix
65 people are tracked at Quanterix (34 in leadership, 6 in board & advisors, 25 in team); the tracked headcount is 471.
| Name | Role | Group |
|---|---|---|
Jen Jalbert | Director Of Manufacturing | Leadership |
Ginger Gillen | Director Of Business Operations | Leadership |
Darrin Crisitello | Chief Commercial Officer (cco) | Leadership |
Mary Ellen Cortizas | Vice President Of CRO And Laboratory Services | Leadership |
Amy Achorn | Director Of Administrative Services | Leadership |
Masoud Toloue | Chief Executive Officer | Leadership |
Erica Bell | Chief People Officer | Leadership |
Vandana Sriram | Chief Financial Officer | Leadership |
Anthony Slattum | Sr Director Customer Care | Leadership |
Dusty Whittemore | Vice President, Global Field Service & Support | Leadership |
Wendy Cirillo | Vice President NA Pharma | Leadership |
Candice Carney | Supply Chain Director | Leadership |
Elle McDermott | Director, Fp&a | Leadership |
Michael Miller | Chief Operating Officer | Leadership |
Veronique Neumeister | Senior Director, Tissue Diagnostics Lab Services | Leadership |
Kirk Stockwood | Vice President Of Sales | Leadership |
Mingwei Zhao | Senior Director, Lab Services | Leadership |
Lisa Sheehan | Vice President Supply Chain | Leadership |
Loan Duong | Associate Director, Revenue Accounting | Leadership |
Fred Carter Jr. | Vice President Of Finance | Leadership |
45 more people are available in the full profile.
Complete people profiles for Quanterix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Quanterix
Quanterix is a publicly listed company on the NASDAQ with ticker symbol QTRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Dec 2017
- Listed onNASDAQ: QTRX
- Listed entityQuanterix Corporation
- Exchange sectorHealth technology
- ISINUS74766Q1013
- Share price$3.15 (-0.32% on the day) · 2026-10-13
- Market capitalisation$149.0M
- EPS (diluted, trailing year)$-2.63
- Volume (last session)749,916
Financials of Quanterix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $138.9M | -$107.2M | -$68.5M |
| 2024 | $137.4M | -$38.5M | -$44.3M |
| 2023 | $122.4M | -$28.4M | -$32.7M |
| 2022 | $105.5M | -$99.6M | -$67.2M |
| 2021 | $110.6M | -$57.7M | -$53.3M |
Detailed financial statements for Quanterix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Quanterix
Quanterix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Akoya Biosciences and UmanDiagnostics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of solutions for rapid proteomic profiling | akoyabio.com | San Francisco, United States | 2015 | Jul 2025 | $20M | |
Rapid ELISA tests for MS, ALS, and PD are developed. | umandiagnostics.com | Umea, Sweden | 2006 | Jun 2019 | $22.5M |
Complete acquisition details for Quanterix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Quanterix
6 dated milestones of Quanterix across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Quanterix is founded.
- Funding First funding round of $185K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires UmanDiagnostics.
- Funding Latest funding round, Grant,.
- Acquisition Acquires Akoya Biosciences.
Competitors of Quanterix
Quanterix has 3 listed competitors in our database, 2 of them funded. They include Bio Rad, Arrakis Therapeutics and NanoString.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bio-rad.com | 1952 | Hercules, United States | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | ||
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| nanostring.com | 2003 | Seattle, United States | $107.93M | 652 | Tools for translational research and molecular diagnosis are developed. |
Detailed competitors of Quanterix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Quanterix
The website of Quanterix (quanterix.com) receives about 46K visits a month.
- Monthly visits46K
▲ 62% vs previous month
Websites whose visitors overlap most with Quanterix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| healthtech.com | 100% | #1,688,467 | View details | ||
| illumina.com | 97% | 672.7K | #61,793 | View details | |
media.nap.edu | media.nap.edu | 91% | – | ||
| raybiotech.com | 83% | 71.1K | #537,358 | View details | |
| azenta.com | 83% | 142.4K | #244,494 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Quanterix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Quanterix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Quanterix
Complete news archive for Quanterix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quanterix
Quanterix was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Quanterix is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Quanterix is a funded company, having raised a total of $99.5M across 15 funding rounds to date. The company's 1st funding round was a Series A of $2.5M, raised on Jul 2008.
Quanterix has 471 employees.
Annual revenue of Quanterix is $138.9M as on Dec 31, 2025.
Quanterix was founded in 2007 in Cambridge, United States, and operates in the biotechnology sector. Assay kits utilizing the Simoa technology are provided for ultra-sensitive biomarker detection. This solution supports research applications across oncology, neurology, cardiology, inflammation, and infectious diseases. Operations focus on enabling disease detection, prognosis, and treatment methods through precise biomarker analysis.
Quanterix's top competitors include NanoString, Arrakis Therapeutics and Bio Rad.
Quanterix offers Simoa Assay Kits, Simoa HD-X Analyzer, and Custom Assay Development.
Yes, Quanterix is publicly traded on NASDAQ under the ticker symbol QTRX.
Quanterix has made 2 acquisitions, including Akoya Biosciences, and UmanDiagnostics.
Quanterix has 14 investors. Key investors include General Electric, T. Rowe Price, Hercules Capital, HHS, and NFL.